Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT04744831 |
| Title | Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer (DESTINY-CRC02) |
| Acronym | DESTINY-CRC02 |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | Yes |
| Sponsors | Daiichi Sankyo, Inc. |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA | ITA | GBR | FRA | ESP | BEL | AUS |
CKB BOOST